All companies
Visit website
Cytonics
OperatingCytonics Corp
Healthcare · Technology · Founded 2006
Developing diagnostics and therapeutics for osteoarthritis
Post-money valuation ⓘ
$110.4M
As of Aug 2025 · from Reg A Offering (2024) · pre-money + amount raised, not a traded price
Total raised
$22,726,741
Across 9 rounds since 2019
Latest share price
$2.30
Reg CF Offering (2026) offering price
Financials
FY2016–FY2025 · from SEC filings · hover any figure for its source$294K
−$564K
2017
$294K
−$564K
2019
$365K
−$977K
2020
$308K
$2.5M
2021
$405K
$2.8M
2022
$418K
−$1.9M
2023
$307K
−$4.5M
2024
$260K
−$8.6M
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Chart shows the most recent 8 fiscal years; 1 earlier year is in the table below.
Metric
FY2016
FY2017
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Income statement
Revenue
$219,935
$294,000
$294,000
$365,169
$307,500
$405,000
$417,500
$306,669
$260,000
Cost of goods sold
$0
$0
$0
$0
$0
$0
$2,370,360
$0
$0
Gross margin
100%
100%
100%
100%
100%
100%
-468%
100%
100%
Net income
-$1,427,521
-$564,490
-$564,490
-$976,922
$2,544,189
$2,844,674
-$1,927,629
-$4,526,921
-$8,585,155
Taxes paid
$0
$0
$0
$0
$0
$0
$0
$0
$0
Balance sheet
Cash
$480,309
$772,330
$772,330
$537,592
$967,757
$1,166,390
$602,933
$2,432,955
$2,147,326
Accounts receivable
$3,000
$42,750
$42,750
$18,417
$123,333
$100,000
$0
$50,000
$50,000
Total assets
$871,544
$1,214,257
$1,214,257
$1,056,608
$1,756,758
$1,437,976
$1,030,187
$2,777,933
$2,412,710
Short-term debt
$51,705
$90,318
$90,318
$157,633
$554,929
$304,246
$176,319
$0
$0
Long-term debt
$0
$794,000
$794,000
$1,961,904
$0
$0
$0
$0
$0
Total liabilities
$51,705
$884,318
$1,219,537
$2,119,537
$554,929
$304,246
$378,336
$1,019,799
$0
Other
Headcount
—
1
1
1
1
1
1
1
1
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$50.8M
post-money
$61.8M
post-money
$69.4M
post-money
$67.5M
post-money
$110.4M
post-money
Cytonics Corporation Stock 2
Cytonics Corporation Preferred Stock 2
Reg CF Offering (2023)
Cytonics Preferred Stock 5
Reg A Offering (2024)
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Reg CF annual-report compliance
Not requiredFiled Form C-TR (terminated reporting)
Filed 5 of 8 annual reports (FY2018–FY2025)
2,544 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 63 filings on EDGARSource: ManualCIK 0001421744Share price $2.30
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.